Beta-adrenergic blocking drugs in breast cancer: a perspective review

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Beta-adrenergic receptor (β-AR) signaling plays a role in inhibiting breast cancer progression and metastasis.
• Beta-blockers, commonly prescribed β-AR antagonists, are hypothesized to potentially impact cancer progression favorably.
• Pharmacoepidemiological studies suggest a possible link between β-blocker use and breast cancer outcomes.

Purpose of the Study:

• To review preclinical, epidemiological, and clinical data on the association between beta-blockers and breast cancer progression.
• To evaluate the potential of targeting the β-AR pathway in breast cancer therapy.

Main Methods:

• Review of preclinical studies on β-AR signaling in cancer progression.
• Analysis of epidemiological studies examining β-blocker exposure and breast cancer.
• Synthesis of available clinical data regarding beta-blocker use in breast cancer.

Main Results:

• Preclinical data indicate β-AR signaling can inhibit processes like invasion, inflammation, angiogenesis, and immune responses in breast cancer.
• Epidemiological studies suggest a potential positive association between β-blocker use and breast cancer progression.
• Current evidence indicates a need for larger observational and randomized clinical studies.

Conclusions:

• Beta-blockers may offer a therapeutic avenue for breast cancer by targeting β-AR signaling.
• Further research, including randomized clinical trials, is essential to determine efficacy, optimal drug selection, biomarkers, and treatment paradigms.
• Beta-blockers are not yet a confirmed therapeutic option for breast cancer patients.